• Progress on biosimilar pipeline paves way for five planned launches by 2020
  • Sandoz now plans a total of 11 biosimilar filings by end 2017 (EU and US) and has already delivered on six
  • Investments of more than USD 1 billion in state of-the-art biomanufacturing facilities, backed by industry-leading capabilities as part of Novartis, positions Sandoz to deliver biosimilars at unprecedented scale

Holzkirchen, June 20, 2016 – Sandoz, a Novartis Division and the global leader in biosimilars, plans to launch five biosimilars of major oncology and …

  • Sandoz’ biosimilar etanercept candidate shows pharmacokinetic (PK) bioequivalence with no clinically meaningful differences in safety, tolerability and immunogenicity to the originator.1

  • Sandoz’ biosimilar rituximab candidate shows PK bioequivalence and similar pharmacodynamics (PD), safety, efficacy and immunogenicity.2

  • Biosimilar etanercept candidate is under regulatory review by EMA* and FDA** and biosimilar rituximab candidate is undergoing EMA review.

Holzkirchen, June 9, 2016 – Sandoz, a …